Birdwatch Note
2023-10-26 21:02:32 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Ivermectin was developed in the late 70's at the Kitasato Institute, Tokyo, Japan. Hailed as a wonder drug Ivermectin has been used safely to eliminate a multitude of parasitic infections across the globe and is regularly prescribed. Use for the novel Covid-19 was experimental https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740/
Written by 47634619D58CC5F821DEF73AA3068D62CBA0B7A6F71779D1810D4306DC5BE6AF
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1717630521470046444
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1717647924501377246
- noteId - 1717647924501377246
- participantId -
- noteAuthorParticipantId - 47634619D58CC5F821DEF73AA3068D62CBA0B7A6F71779D1810D4306DC5BE6AF Participant Details
- createdAtMillis - 1698354152223
- tweetId - 1717630521470046444
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Ivermectin was developed in the late 70's at the Kitasato Institute, Tokyo, Japan. Hailed as a wonder drug Ivermectin has been used safely to eliminate a multitude of parasitic infections across the globe and is regularly prescribed. Use for the novel Covid-19 was experimental https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740/
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-10-26 21:02:32 UTC (1698354152223) |
1969-12-31 23:59:59 UTC (-1) |
2023-10-27 04:51:28 UTC (1698382288906) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-10-26 18:56:24 -0500 | Rating Details | |
| 2023-10-26 18:31:10 -0500 | Rating Details | |
| 2023-10-26 17:54:18 -0500 | Rating Details | |
| 2023-10-26 17:44:39 -0500 | Rating Details | |
| 2023-10-26 17:23:04 -0500 | Rating Details | |
| 2023-10-26 17:21:08 -0500 | Rating Details | |
| 2023-10-26 17:11:01 -0500 | Rating Details | |
| 2023-10-26 16:47:11 -0500 | Rating Details | |
| 2023-10-27 13:38:37 -0500 | Rating Details | |
| 2023-10-27 10:54:23 -0500 | Rating Details | |
| 2023-10-27 10:48:38 -0500 | Rating Details | |
| 2023-10-27 09:58:28 -0500 | Rating Details | |
| 2023-10-27 09:52:28 -0500 | Rating Details | |
| 2023-10-27 09:30:39 -0500 | Rating Details | |
| 2023-10-27 08:32:36 -0500 | Rating Details | |
| 2023-10-27 07:49:49 -0500 | Rating Details | |
| 2023-10-27 07:37:10 -0500 | Rating Details | |
| 2023-10-27 07:32:44 -0500 | Rating Details | |
| 2023-10-27 03:15:52 -0500 | Rating Details | |
| 2023-10-26 22:45:21 -0500 | Rating Details | |
| 2023-10-26 22:35:51 -0500 | Rating Details | |
| 2023-10-26 20:42:43 -0500 | Rating Details | |
| 2023-10-26 19:43:20 -0500 | Rating Details | |
| 2023-10-27 21:36:23 -0500 | Rating Details | |
| 2023-10-27 15:00:06 -0500 | Rating Details | |
| 2023-10-27 11:47:39 -0500 | Rating Details | |
| 2023-10-27 11:31:52 -0500 | Rating Details | |
| 2023-10-27 11:12:43 -0500 | Rating Details | |
| 2023-10-27 11:03:24 -0500 | Rating Details | |
| 2023-10-27 10:19:14 -0500 | Rating Details | |
| 2023-10-27 09:29:27 -0500 | Rating Details | |
| 2023-10-27 09:24:32 -0500 | Rating Details | |
| 2023-10-27 08:55:26 -0500 | Rating Details | |
| 2023-10-27 08:49:30 -0500 | Rating Details | |
| 2023-10-27 08:42:01 -0500 | Rating Details | |
| 2023-10-27 08:23:32 -0500 | Rating Details | |
| 2023-10-27 08:21:56 -0500 | Rating Details | |
| 2023-10-27 08:13:51 -0500 | Rating Details | |
| 2023-10-27 07:38:05 -0500 | Rating Details | |
| 2023-10-27 07:06:57 -0500 | Rating Details | |
| 2023-10-27 06:05:04 -0500 | Rating Details | |
| 2023-10-27 05:56:09 -0500 | Rating Details | |
| 2023-10-27 02:45:12 -0500 | Rating Details | |
| 2023-10-27 02:14:01 -0500 | Rating Details | |
| 2023-10-27 01:06:29 -0500 | Rating Details | |
| 2023-10-26 22:20:27 -0500 | Rating Details | |
| 2023-10-26 21:41:58 -0500 | Rating Details | |
| 2023-10-26 21:16:39 -0500 | Rating Details | |
| 2023-10-26 20:49:22 -0500 | Rating Details | |
| 2023-10-26 19:09:56 -0500 | Rating Details | |
| 2023-10-26 19:07:12 -0500 | Rating Details | |
| 2023-10-26 18:41:37 -0500 | Rating Details | |
| 2023-10-26 18:03:52 -0500 | Rating Details | |
| 2023-10-26 17:55:05 -0500 | Rating Details | |
| 2023-10-26 17:35:11 -0500 | Rating Details | |
| 2023-10-26 17:28:44 -0500 | Rating Details | |
| 2023-10-26 16:38:43 -0500 | Rating Details | |
| 2023-10-26 16:16:58 -0500 | Rating Details | |
| 2023-10-30 18:50:32 -0500 | Rating Details |